Side-by-side · Research reference
MT-1vsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED9/51 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
MT-1
Pancragen
Primary target
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Yes — preserves physiological glucose-insulin response
Origin
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
MT-1
Pancragen
Standard dose
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
—
Frequency
Every 60 days
Sustained release implant — no daily administration required.
Once daily for 10 daysGoncharova 2014
Evidence basis
Phase 3 RCT / FDA-approved orphan drug
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Indication
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
—
Duration
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
—
Stability
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
MT-1
Pancragen
Nausea
Common (>10%) — mild, transient
—
Implant site reaction
Erythema, bruising, tenderness at insertion site
—
Hyperpigmentation
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
—
Melanocytic changes
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
—
Headache
Occasional (MC1R-independent melanocortin effects)
—
Photosensitivity (paradoxical)
Rare phototoxic reactions despite melanin increase
—
Contamination risk (unregulated)
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Pancragen
—Relative Contraindications
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
MT-1
Pancragen
1. Implant insertion
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Site care
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Release kinetics
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Repeat dosing
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Monitoring
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
—